Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037)

Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037)

Background: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor abiraterone irreversibly inhibits androgen biosynthesis. The Cancer of the Ovary Ab...

Full description

Bibliographic Details
Main Authors: Susana Banerjee, Holly Tovey, Rebecca Bowen, Elizabeth Folkerd, Lucy Kilburn, Jennifer McLachlan, Marcia Hall, Nina Tunariu, Ayoma Attygalle, Joao Paulo Da Silveira Nogueira Lima, Sophie Perry, Peter Chatfield, Margaret Hills, Stan Kaye, Gert Attard, Mitch Dowsett, Judith M. Bliss
Format: Article
Language:English
Published: SAGE Publishing 2020-12-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835920975352

Internet

https://doi.org/10.1177/1758835920975352

Similar Items